Savara (SVRA) Other Non-Current Liabilities (2016 - 2025)
Savara (SVRA) reported Other Non-Current Liabilities of $44000.0 for Q1 2025, down 78.85% year-over-year from $208000.0 in Q1 2024, and down 49.43% quarter-over-quarter from $87000.0 in Q4 2024.
Savara (SVRA) Other Non-Current Liabilities (2016 - 2025) Analysis & Trends
Savara (SVRA) has 10 years of Other Non-Current Liabilities data on file, last reported at $44000.0 in Q1 2025.
- Other Non-Current Liabilities for Q1 2025 came in at $44000.0, down 78.85% year-over-year; the trailing twelve-month figure through Mar 2025 was $44000.0 (down 78.85% YoY), and the FY2024 annual result was $87000.0, down 64.78% from the prior year.
- Other Non-Current Liabilities declined to $44000.0 in Q1 2025 per SVRA's latest filing, from $87000.0 in the prior quarter.
- Over five years, Other Non-Current Liabilities peaked at $284000.0 in Q3 2023 and troughed at $20000.0 in Q2 2023.
- A 5-year average of $104823.5 and a median of $87000.0 in 2022 frame the typical range for Other Non-Current Liabilities.
- The sharpest annual moves came in 2021 and 2024: Other Non-Current Liabilities sank 99.03% in 2021, then jumped 745.0% in 2024.
- A 5-year view of Other Non-Current Liabilities shows it stood at $117000.0 in 2021, then slumped by 53.85% to $54000.0 in 2022, then surged by 357.41% to $247000.0 in 2023, then plunged by 64.78% to $87000.0 in 2024, then sank by 49.43% to $44000.0 in 2025.
- Business Quant data shows SVRA's Other Non-Current Liabilities at $44000.0 in Q1 2025, $87000.0 in Q4 2024, and $128000.0 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - |
| 10 | Savara | 1.33 Bn | 1.33 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 44,000.00 |
| Dec 31, 2024 | 87,000.00 |
| Sep 30, 2024 | 128,000.00 |
| Jun 30, 2024 | 169,000.00 |
| Mar 31, 2024 | 208,000.00 |
| Dec 31, 2023 | 247,000.00 |
| Sep 30, 2023 | 284,000.00 |
| Jun 30, 2023 | 20,000.00 |
| Mar 31, 2023 | 37,000.00 |
| Dec 31, 2022 | 54,000.00 |
| Sep 30, 2022 | 71,000.00 |
| Jun 30, 2022 | 87,000.00 |
| Mar 31, 2022 | 102,000.00 |
| Dec 31, 2021 | 117,000.00 |
| Sep 30, 2021 | 34,000.00 |
| Jun 30, 2021 | 35,000.00 |
| Mar 31, 2021 | 58,000.00 |
| Dec 31, 2020 | 84,000.00 |
| Sep 30, 2020 | 3.10 Mn |
| Jun 30, 2020 | 3.00 Mn |